UCB's Antibody Patent Win Against Yeda Backed By Fed. Circ.
The Federal Circuit on Thursday affirmed a lower court's ruling that UCB Inc.'s Cimzia brand antibody used to treat Crohn's disease and arthritis does not infringe a patent owned by Yeda...To view the full article, register now.
Already a subscriber? Click here to view full article